VF
ADAP

Virtu Financial’s Adaptimmune Therapeutics ADAP Stock Holding History

Virtu Financial’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-122,696
Closed -$66K – 1288
2024
Q4 		$66K Buy
122,696
+21,688
+21% +$15.8K ﹤0.01% 1108
2024
Q3 		$96K Buy
101,008
+21,769
+27% +$24.7K 0.01% 920
2024
Q2 		$77K Buy
+79,239
New +$87K 0.01% 853
2024
Q1 		– Sell
-28,406
Closed -$23K – 1354
2023
Q4 		$23K Buy
+28,406
New +$16K ﹤0.01% 1301
2023
Q2 		– Sell
-88,234
Closed -$96K – 1461
2023
Q1 		$96K Buy
88,234
+58,131
+193% +$90K 0.01% 993
2022
Q4 		$44K Sell
30,103
-10,400
-26% -$16.8K 0.01% 1105
2022
Q3 		$44K Buy
40,503
+23,175
+134% +$42.6K ﹤0.01% 1229
2022
Q2 		$29K Sell
17,328
-7,142
-29% -$12.3K ﹤0.01% 1253
2022
Q1 		$50K Buy
+24,470
New +$66K ﹤0.01% 1132
2021
Q4 		– Sell
-47,542
Closed -$246K – 1646
2021
Q3 		$246K Buy
+47,542
New +$213K 0.02% 811
2020
Q3 		– Sell
-19,845
Closed -$199K – 994
2020
Q2 		$199K Buy
+19,845
New +$125K 0.02% 733
2018
Q1 		– Sell
-60,473
Closed -$404K – 1889
2017
Q4 		$404K Buy
60,473
+32,422
+116% +$250K 0.02% 1009
2017
Q3 		$230K Buy
+28,051
New +$175K 0.01% 1679

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial's ADAP Position: Q1 2025 in Review

Virtu Financial sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 122,696 shares — an estimated $66K sold.

Virtu Financial first reported a position in ADAP in Q3 2017 and held it in 13 quarters. The position peaked at $404K in Q4 2017. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Virtu Financial reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtu Financial sold 122,696 Adaptimmune Therapeutics shares in Q1 2025, an estimated $66K.
  • Virtu Financial first reported a position in Adaptimmune Therapeutics in Q3 2017 and held it in 13 quarters.
  • Virtu Financial's Adaptimmune Therapeutics position peaked at $404K in Q4 2017.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.